NCT04732273 The Swiss Childhood Cancer Survivor Study - Follow-up (SCCSS-FollowUp)
| NCT ID | NCT04732273 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Bern |
| Condition | Late Effect |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-06-20 |
| Primary Completion | 2071-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-06-20 with a primary completion date of 2071-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The SCCSS-FollowUp is a national, multicenter cohort study designed to investigate late effects in childhood cancer survivors in a prospective and longitudinal way. The study is embedded in regular follow-up care and inclusion in the study takes place in a step-wise approach. The investigators collect data from clinical examinations, laboratory and functional tests, and questionnaires to learn more about late effects of childhood cancer treatments.
Eligibility Criteria
This prospective cohort study is based on the Childhood Cancer Registry (ChCR), a national, population-based cancer registry that includes all children and adolescents in Switzerland who were diagnosed with cancer at age 0-20 years. It includes patients diagnosed with leukemia, lymphoma, central nervous system tumors, and malignant solid tumors or Langerhans cell histiocytosis. Inclusion Criteria: * Registered in the Childhood Cancer Registry (ChCR) or treated and followed-up in a Swiss pediatric oncology (SPOG) clinic, but not registered in the ChCR because of residency in neighboring countries * Diagnosed at age 0 - 20 years * Childhood cancer treatment completed * All age categories at time of inclusion in the study (children, adolescents, adults) * Written informed consent Exclusion criteria: * Childhood cancer survivors in a palliative or relapsed situation where no follow-up examinations are foreseen.
Contact & Investigator
Claudia E Kuehni, MD
PRINCIPAL INVESTIGATOR
Institute of Social and Preventive Medicine, University of Bern
Frequently Asked Questions
Who can join the NCT04732273 clinical trial?
This trial is open to participants of all sexes, studying Late Effect. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04732273 currently recruiting?
Yes, NCT04732273 is actively recruiting participants. Contact the research team at claudia.kuehni@unibe.ch for enrollment information.
Where is the NCT04732273 trial being conducted?
This trial is being conducted at Basel, Switzerland, Bern, Switzerland, Geneva, Switzerland.
Who is sponsoring the NCT04732273 clinical trial?
NCT04732273 is sponsored by University of Bern. The principal investigator is Claudia E Kuehni, MD at Institute of Social and Preventive Medicine, University of Bern. The trial plans to enroll 3,000 participants.